You may think you know how much Intel is struggling, but the reality is worse. The once-mighty American innovation powerhouse is losing market share in multiple areas that are critical to its ...

Gilead Sciences, GSK, ViiV Healthcare 1 to 3 years In June 2024, results from a trial of a new medicine to prevent HIV were announced—and they were jaw-dropping. Lenacapavir, a treatment ...

Intel plans to reach $15 billion in annual external foundry revenue by 2030. That ambitious target requires Intel 18A to deliver on its promises and launch on time. Any delays or missteps could be ...